Literature DB >> 12538487

Function of nuclear factor kappaB in pancreatic cancer metastasis.

Shuichi Fujioka1, Guido M Sclabas, Christian Schmidt, Wayne A Frederick, Qiang G Dong, James L Abbruzzese, Douglas B Evans, Cheryl Baker, Paul J Chiao.   

Abstract

PURPOSE: We seek to elucidate the role of constitutive nuclear factor kappaB (NFkappaB) activity in human pancreatic cancer cells. We have demonstrated that the transcription factor NFkappaB is activated constitutively in human pancreatic adenocarcinoma and human pancreatic cancer cell lines but not in normal pancreatic tissues or in immortalized/nontumorigenic pancreatic epithelial cells, suggesting that NFkappaB plays a critical role in development of pancreatic adenocarcinoma. EXPERIMENTAL
DESIGN: By pooling all of the puromycin resistant clones after inhibitor of nuclear factor-kappaB phosphorylation mutant (IkappaBalphaM) retroviral infection, we generated pancreatic tumor cell lines that express a IkappaBalphaM (S32, 36A) that blocks NFkappaB activity. Inhibition of metastatic phenotype was assayed in an orthotopic nude mouse model. NFkappaB activity was determined by electrophoretic mobility shift assay, and the expression of NFkappaB downstream target genes was analyzed by Northern, Western, and immunohistochemical analyses.
RESULTS: We showed that inhibiting constitutive NFkappaB activity by expressing IkappaBalphaM suppresses liver metastasis, but not tumorigenesis, from the metastatic human pancreatic tumor cell line AsPc-1 in an orthotopic nude mouse model. Furthermore, inhibiting NFkappaB activation by expressing IkappaBalphaM significantly reduced in vivo expression of a major proangiogenic molecule, vascular endothelial growth factor, and, hence, decreased neoplastic angiogenesis. Inhibiting NFkappaB activation by expressing IkappaBalphaM and using pharmacologic NFkappaB inhibitor PS-341 also significantly reduced cytokine-induced vascular endothelial growth factor and interleukin-8 expression in AsPc-1 pancreatic cancer cells.
CONCLUSION: These results demonstrated that the inhibition of NFkappaB signaling can suppress the angiogenic potential and metastasis of pancreatic cancer, and suggest that the NFkappaB signaling pathway is a potential target for anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538487

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  99 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells.

Authors:  Amit Deorukhkar; Shujun Shentu; Hee Chul Park; Parmeswaran Diagaradjane; Vinay Puduvalli; Bharat Aggarwal; Sushovan Guha; Sunil Krishnan
Journal:  Pancreas       Date:  2010-11       Impact factor: 3.327

3.  Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.

Authors:  Ajaikumar B Kunnumakkara; Bokyung Sung; Jayaraj Ravindran; Parmeswaran Diagaradjane; Amit Deorukhkar; Sanjit Dey; Cemile Koca; Zhimin Tong; Juri G Gelovani; Sushovan Guha; Sunil Krishnan; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2011-11-09       Impact factor: 7.396

Review 4.  NF-kappaB in pancreatic cancer.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Douglas B Evans; Paul J Chiao
Journal:  Int J Gastrointest Cancer       Date:  2003

Review 5.  Current methods for assaying angiogenesis in vitro and in vivo.

Authors:  Carolyn A Staton; Stephen M Stribbling; Simon Tazzyman; Russell Hughes; Nicola J Brown; Claire E Lewis
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

6.  Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.

Authors:  Annette Wunderlich; Silvia Roth; Annette Ramaswamy; Brandon H Greene; Cornelia Brendel; Ulrike Hinterseher; Detlef K Bartsch; Sebastian Hoffmann
Journal:  Endocrine       Date:  2012-04-05       Impact factor: 3.633

Review 7.  Chemoprevention strategies for pancreatic cancer.

Authors:  Silvia D Stan; Shivendra V Singh; Randall E Brand
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-04       Impact factor: 46.802

Review 8.  Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis.

Authors:  André L Mihaljevic; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Langenbecks Arch Surg       Date:  2010-03-18       Impact factor: 3.445

9.  Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.

Authors:  Jingjing Gong; Jianping Xie; Roble Bedolla; Paul Rivas; Divya Chakravarthy; James W Freeman; Robert Reddick; Scott Kopetz; Amanda Peterson; Huamin Wang; Susan M Fischer; Addanki P Kumar
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

10.  TGF-β1 mediates the effects of aspirin on colonic tumor cell proliferation and apoptosis.

Authors:  Yuyi Wang; Chi Du; Nan Zhang; Mei Li; Yanyang Liu; Maoyuan Zhao; Feng Wang; Feng Luo
Journal:  Oncol Lett       Date:  2018-02-14       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.